CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Aug. 4, 2021—Immunovia has received approval to begin patient testing for the IMMray PanCan-d blood test for the early detection of pancreatic cancer. Approval was received Aug. 3 from the Massachusetts Department of Public Health, and the company received its CLIA Certificate of Registration on June 21.
“We are extremely pleased to have achieved this important milestone and to be able to launch the first noninvasive, highly accurate blood test that can help detect pancreatic cancer in early stages,” Patrik Dahlen, CEO of Immunovia, said in a press statement. “The IMMray PanCan-d test meets a huge clinical need and our ambition is to make the test available to individuals in all the high-risk groups for pancreatic cancer. As a first step, we will launch the test for the familial/hereditary high-risk group.”